Breast cancer

23 October 2007

Some breast cancers don't respond to chemotherapy

An analysis of the results of several studies confirmed that chemotherapy offers little or no survival benefits for young women with oestrogen receptor-positive breast cancers.

An analysis of the results of several studies confirm previous reports suggesting that chemotherapy offers little or no survival benefits for young women with oestrogen receptor (ER)-positive breast cancers and, if given, it should not be the sole second-phase, or "adjuvant" therapy.

"Developing breast cancer at a young age is very worrying in terms of survival," lead researcher Dr Jos J. A. van der Hage, from Leiden University in the Netherlands, said in a statement. "But some young women may be undergoing not only unpleasant but also unnecessary chemotherapy."

In the current analysis, the researchers examined data from 480 women with early-stage breast cancer enrolled in one of four EORTC (European Organization for Research and Treatment of Cancer) trials. All of the subjects were pre-menopausal - younger than 40 years of age - and the average follow-up period was 7.6 years.

During follow-up, 155 patients died or experienced a distant recurrence, according to the report appearing in the current online issue of Breast Cancer Research.

Chemo showed no effect
Patients with ER-positive cancers were significantly more likely to have a longer overall survival than those with ER-negative cancers, the team reports.

Among the patients who received prolonged adjuvant chemotherapy, however, the difference in survival rates was minimal (70 percent versus 75 percent, favouring the ER-negative group, and rates of metastasis-free survival were 59 percent versus 70 percent, respectively).

These results suggest that chemotherapy had a beneficial effect for women with ER-negative tumours, but had minimal or no effect on ER-positive cancers.

Similar survival differences were noted for women with or without progesterone receptor-positive tumours, the report indicates.

"Adjuvant chemotherapy is a well established, but ineffective treatment in ER-positive breast cancer patients aged 40 years or less," van der Hage emphasised. "Hormone responsiveness is the key to tailoring therapy in the future fight against this disease for young women." – (Reuters Health)

SOURCE: Breast Cancer Research, October 10, 2007.

Read more:
Oestrogen linked to cancer
Hormones up breast cancer risk


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules